Long et al., 2023 - Google Patents
Reoperation and pain-related outcomes after hysterectomy for endometriosis by oophorectomy statusLong et al., 2023
- Document ID
- 1627882020166732531
- Author
- Long A
- Kaur P
- Lukey A
- Allaire C
- Kwon J
- Talhouk A
- Yong P
- Hanley G
- Publication year
- Publication venue
- American Journal of Obstetrics and Gynecology
External Links
Snippet
Background More research is needed that compares the outcomes between those who underwent a hysterectomy for endometriosis with conservation of one or both ovaries and those who underwent a hysterectomy with bilateral salpingo-oophorectomy. Objective This …
- 238000009802 hysterectomy 0 title abstract description 184
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wouk et al. | Abnormal uterine bleeding in premenopausal women | |
Rodriguez et al. | Progestogen‐releasing intrauterine systems for heavy menstrual bleeding | |
Rodriguez et al. | Interventions for heavy menstrual bleeding; overview of Cochrane reviews and network meta‐analysis | |
Marret et al. | Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause | |
Armstrong et al. | Diagnosis and management of endometrial hyperplasia | |
Gallos et al. | Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis | |
Rizk et al. | Recurrence of endometriosis after hysterectomy | |
Lang et al. | Dienogest for treatment of endometriosis in Chinese women: a placebo-controlled, randomized, double-blind phase 3 study | |
Missmer et al. | In utero exposures and the incidence of endometriosis | |
Gustofson et al. | Endometriosis and the appendix: a case series and comprehensive review of the literature | |
Shim et al. | Dysmenorrhea and endometriosis in transgender adolescents | |
Oguz et al. | The role of hormone replacement therapy in endometrial polyp formation | |
Grimstad et al. | Breakthrough bleeding in transgender and gender diverse adolescents and young adults on long-term testosterone | |
Bakas et al. | Hysteroscopic resection of uterine septum and reproductive outcome in women with unexplained infertility | |
Long et al. | Reoperation and pain-related outcomes after hysterectomy for endometriosis by oophorectomy status | |
Brucker et al. | Clinical characteristics indicating adenomyosis coexisting with leiomyomas: a retrospective, questionnaire-based study | |
Baker et al. | Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women | |
Merrill et al. | Risk estimates of hysterectomy and selected conditions commonly treated with hysterectomy | |
Lucchini et al. | Updates on conservative management of endometrial cancer in patients younger than 45 years | |
Matorras et al. | Endometriosis and spontaneous abortion rate: a cohort study in infertile women | |
Dason et al. | Guideline No. 437: diagnosis and management of adenomyosis | |
Marschalek et al. | Anatomic outcomes after pelvic-organ-prolapse surgery—comparing uterine preservation with hysterectomy | |
Health Quality Ontario | Levonorgestrel-releasing intrauterine system (52 mg) for idiopathic heavy menstrual bleeding: a health technology assessment | |
Gelderblom et al. | The effect of opportunistic salpingectomy for primary prevention of ovarian cancer on ovarian reserve: a systematic review and meta-analysis | |
Elford et al. | Novel treatment of a patient with secondary infertility due to retained fetal bone |